dc.contributor.author | Decara, Juan | |
dc.contributor.author | Rivera, Patricia | |
dc.contributor.author | López-Gambero, Antonio Jesús | |
dc.contributor.author | Serrano, Antonia | |
dc.contributor.author | Pavón, Francisco-Javier | |
dc.contributor.author | Baixeras, Elena | |
dc.contributor.author | Rodríguez de Fonseca, Fernando | |
dc.contributor.author | Suárez, Juan | |
dc.date.accessioned | 2024-02-12T19:46:24Z | |
dc.date.available | 2024-02-12T19:46:24Z | |
dc.date.issued | 2020-05-27 | |
dc.identifier.other | http://hdl.handle.net/10668/3629 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/18058 | |
dc.description.abstract | The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that promote ligand-dependent transcription of target genes that regulate energy production, lipid metabolism, and inflammation. The PPAR superfamily comprises three subtypes, PPARα, PPARγ, and PPARβ/δ, with differential tissue distributions. In addition to their different roles in the regulation of energy balance and carbohydrate and lipid metabolism, an emerging function of PPARs includes normal homeostasis of intestinal tissue. PPARα activation represses NF-κB signaling, which decreases the inflammatory cytokine production by different cell types, while PPARγ ligands can inhibit activation of macrophages and the production of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and Il-1β. In this regard, the anti-inflammatory responses induced by PPAR activation might restore physiopathological imbalances associated with inflammatory bowel diseases (IBD). Thus, PPARs and their ligands have important therapeutic potential. This review briefly discusses the roles of PPARs in the physiopathology and therapies of the most important IBDs, ulcerative colitis (UC), and Crohn's disease (CD), as well some new experimental compounds with PPAR activity as promising drugs for IBD treatment. | |
dc.description.sponsorship | This study was supported by the following research projects and programs: Proyecto de Investigación en Salud “PI-0139-2018” funded by Consejerı́a de Salud y Familias, Junta de Andalucı́a; “DTS19/00125” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (ERDF) “A way to make Europe”; Proyecto de Investigación en Salud “PI19/01577” funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (ERDF) “A way to make Europe”; AS and JS hold “Miguel Servet” research contracts (CP14/00173 and CPII17/00024 respectively) from the ISCIII and co-funded by European Social Fund “Investing in your future” PR holds a “Sara Borrell” research contract (CD16/00067) from the ISCIII and co-funded by European Social Fund “Investing in your future” FP holds a “Programa Nicolás Monardes” contract (C1-0049-2019) from Servicio Andaluz de Salud, Junta de Andalucía. | |
dc.language.iso | eng | |
dc.publisher | Frontiers Media | |
dc.type.hasVersion | VoR | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | PPARa | |
dc.subject | PPARg | |
dc.subject | PPARb/d | |
dc.subject | Inflammatory bowel diseases | |
dc.subject | Ulcerative colitis | |
dc.subject | Crohn's disease | |
dc.subject | Receptores activados del proliferador del peroxisoma | |
dc.subject | Enfermedades inflamatorias del intestino | |
dc.subject | Colitis ulcerosa | |
dc.subject | Enfermedad de Crohn | |
dc.subject.mesh | Peroxisome Proliferator-Activated Receptors | |
dc.subject.mesh | Inflammatory Bowel Diseases | |
dc.subject.mesh | Colitis, Ulcerative | |
dc.subject.mesh | Crohn Disease | |
dc.subject.mesh | Lipid Metabolism | |
dc.subject.mesh | Ligands | |
dc.subject.mesh | NF-kappa B | |
dc.subject.mesh | PPAR gamma | |
dc.subject.mesh | Inflammation | |
dc.subject.mesh | Anti-Inflammatory Agents | |
dc.subject.mesh | Homeostasis | |
dc.subject.mesh | Pharmaceutical Preparations | |
dc.title | Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases | |
dc.type | review article | |
dc.rights.license | Attribution 4.0 International | * |
dc.identifier.pubmedID | 32536865 | es_ES |
dc.identifier.doi | 10.3389/fphar.2020.00730 | |
dc.identifier.e-issn | 1663-9812 | es_ES |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fphar.2020.00730/full | es |
dc.identifier.journal | Frontiers in Pharmacology | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.contributor.authoraffiliation | [Decara,J; López-Gambero,AJ; Serrano,A; Pavón, Francisco-Javier; Rodríguez de Fonseca,F; Suárez,J] UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [Rivera,P] Departamento de Endocrinología, Fundación Investigación Biomédica del Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Pavón,FJ] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) and UGC del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain. [Baixeras,E] Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Málaga, IBIMA, Málaga, Spain. | |